Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.43 USD
-0.01 (-0.05%)
Updated Sep 18, 2024 04:00 PM ET
Pre-Market: $20.56 +0.13 (0.64%) 8:02 AM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 221 - 240 ( 428 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Major Overhang Removed, We Believe; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focus Remains on FDA Filing Acceptance and Approval; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Filed; Acceptance Decision Likely by the end of May
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse on the Cusp of a LEMS Approval While Add-on Data Continue to Cook; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A